DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lv9gmc/mavrilimumab) has announced the addition of the "Mavrilimumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering.
Mavrilimumab, also known as CAM3001, is in Phase IIb of development for RA by MedImmune, a subsidiary of AstraZeneca. It is a human mAb targeted against the alpha subunit of the GM-CSF receptor. GM-CSF levels are elevated in the serum, synovial fluid, and synoviocytes of patients with RA. Inhibition of GM-CSF activity is proposed to reduce the activation, differentiation, and recruitment of macrophages and neutrophils in the damaged and inflamed joints of RA patients.
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Mavrilimumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Mavrilimumab for the top 6 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Etiology and Pathophysiology
3.4 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.2 Treatment Guidelines
4.1.3 Leading Prescribed Drugs for the Treatment of RA
4.1.4 Clinical Practice
5 Competitive Assessment
6 Unmet Need and Opportunity
6.2 Development of Cost-Effective Therapies
6.3 Biomarkers to Predict Responsiveness to Therapy
6.4 Early Diagnosis of RA
6.5 Personalized Treatment Approach
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
For more information visit http://www.researchandmarkets.com/research/lv9gmc/mavrilimumab